Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Randomised, Phase 2 Study in Patients With Advanced Solid Tumours to Determine Effect of Food Upon Pharmacokinetics of a Single Oral Dose of Cediranib (AZD2171, Recentin™), Followed by an Assessment of the Safety & Tolerability of Fixed and Individualised Daily Dosing

NCT00306891 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00306891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00306891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Randomised, Phase 2 Study in Patients With Advanced Solid Tumours to Determine Effect of Food Upon Pharmacokinetics of a Single Oral Dose of Cediranib (AZD2171, Recentin™), Followed by an Assessment of the Safety & Tolerability of Fixed and Individualised Daily Dosing
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2006
Completion date
September 30, 2008
Enrollment
60 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer